drugset
Drugs / recombinant tissue plasminogen activator
last change Apr 2013 re-read 3 minutes ago

recombinant tissue plasminogen activator

also known as rt-PA

Protein / enzyme biologic

Developed for
stroke disorder
Investigated by
Joseph Broderick · Medical University of South Carolina · National Institute of Neurological Disorders and Stroke (NINDS) · University of Calgary

Trials 1

today NCT00359424 · Ph 3
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00359424 Aug 2006 → Jul 2012 stroke disorder Joseph Broderick Terminated Missed primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as recombinant tissue plasminogen activator “Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy” NCT00359424 ↗
Known as rt-PA ClinicalTrials.gov intervention name — accepted as the source's own label NCT00359424 ↗
Modality Protein / enzyme biologic “Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy” NCT00359424 ↗
Route Intravenous “administered intravenously over one hour” NCT00359424 ↗